Supernus Pharmaceuticals (SUPN) Asset Writedowns and Impairment (2023 - 2026)

Supernus Pharmaceuticals (SUPN) has 4 years of Asset Writedowns and Impairment data on file, last reported at $1.8 million in Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $1.8 million, up 231.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 792.9% YoY), and the FY2023 annual result was $20.2 million, changed N/A from the prior year.
• Asset Writedowns and Impairment rose to $1.8 million in Q1 2026 per SUPN's latest filing, from -$1.2 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $20.2 million in Q4 2023 and troughed at -$2.0 million in Q4 2024.
• A 4-year average of $2.2 million and a median of $638500.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2025 and 2026: Asset Writedowns and Impairment slumped 724.14% in 2025, then jumped 231.81% in 2026.
• A 4-year view of Asset Writedowns and Impairment shows it stood at $20.2 million in 2023, then tumbled by 109.87% to -$2.0 million in 2024, then surged by 38.38% to -$1.2 million in 2025, then soared by 247.8% to $1.8 million in 2026.
• Business Quant data shows SUPN's Asset Writedowns and Impairment at $1.8 million in Q1 2026, -$1.2 million in Q4 2025, and -$239000.0 in Q3 2025.